(33) Genetic tools, such as CRISPR-Cas9, facilitate precise manipulation of glioma-related genes like TP53, NF1, and RB1, enabling the study of gene-environment interactions and the impact of potential carcinogens. This evidence concerns the gene TP53 and central nervous system cancer.